Aurelija Jucaite
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aurelija Jucaite has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
L. Farde
4 shared publications- Christer Halldin
Department of Biophysics and Radiation Biology, HUN-REN TKI, Semmelweis University, 1094 Budapest, Hungary
3 shared publications P. Karlsson
Department of Clinical Neuroscience, Stockholm Brain Institute, Karolinska Institutet, Stockholm, Sweden
2 shared publicationsA. Cross
1 shared publicationA. Forsberg
1 shared publicationA. Takano
1 shared publication
Latest Publications
- Open Access
- 29 November 2018
- Published by Springer Nature in EJNMMI Research
- Vol. 8 (1) , 102
Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function
The PET radioligand (R)-[11C]PK11195 is used to quantify the 18-kDa translocator protein (TSPO), a marker for glial activation. Since there is no brain region devoid of TSPO, an arterial input function (AIF) is ideally required for quantification of binding. However, obtaining an AIF is experimentally demanding, is sometimes uncomfortable for participants, and can introduce additional measurement error during quantification. The objective of this study was to perform an evaluation of the test-retest reliability and convergent validity of techniques used for quantifying (R)-[11C]PK11195 binding without an AIF in clinical studies. Data from six healthy individuals who participated in two PET examinations, 6 weeks apart, were analyzed. Regional non-displaceable binding potential (BPND) values were calculated using the simplified reference tissue model, with either cerebellum as reference region or a reference input derived using supervised cluster analysis (SVCA). Standardized uptake values (SUVs) were estimated for the time interval of 40–60 min. Test-retest reliability for BPND estimates were poor (80% of ICCs < 0.5). BPND estimates derived without an AIF were not correlated with BPND, total or specific distribution volume from the 2TCM using an AIF (all R2 < 12%). SUVs showed moderate reliability but no correlation to any other outcome measure. Caution is warranted when interpreting patient-control comparisons employing (R)-[11C]PK11195 outcome measures obtained without an AIF.
- 29 November 2018
- Published by Springer Nature in EJNMMI Research
- Vol. 8 (1) , 102
Open AccessTest-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function
The PET radioligand (R)-[11C]PK11195 is used to quantify the 18-kDa translocator protein (TSPO), a marker for glial activation. Since there is no brain region devoid of TSPO, an arterial input function (AIF) is ideally required for quantification of binding. However, obtaining an AIF is experimentally demanding, is sometimes uncomfortable for participants, and can introduce additional measurement error during quantification. The objective of this study was to perform an evaluation of the test-retest reliability and convergent validity of techniques used for quantifying (R)-[11C]PK11195 binding without an AIF in clinical studies. Data from six healthy individuals who participated in two PET examinations, 6 weeks apart, were analyzed. Regional non-displaceable binding potential (BPND) values were calculated using the simplified reference tissue model, with either cerebellum as reference region or a reference input derived using supervised cluster analysis (SVCA). Standardized uptake values (SUVs) were estimated for the time interval of 40–60 min. Test-retest reliability for BPND estimates were poor (80% of ICCs < 0.5). BPND estimates derived without an AIF were not correlated with BPND, total or specific distribution volume from the 2TCM using an AIF (all R2 < 12%). SUVs showed moderate reliability but no correlation to any other outcome measure. Caution is warranted when interpreting patient-control comparisons employing (R)-[11C]PK11195 outcome measures obtained without an AIF.
- 1 September 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25, S274
P.1.g.069 Relationship between dose, plasma concentration and GABA-A receptor occupancy by partial GABA-A receptor modulators
- 1 September 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25, S274
P.1.g.069 Relationship between dose, plasma concentration and GABA-A receptor occupancy by partial GABA-A receptor modulators
- 3 May 2013
- Published by Springer Nature in Psychopharmacology
- Vol. 231 (6) , 1251-1265
A randomized, double-blind, placebo-controlled crossover study of α4β2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder
Rationale Stimulation of nicotinic cholinergic systems has been shown to alleviate ADHD symptoms and to improve cognitive performance. AZD1446 is a selective α4β2* nicotinic acetylcholine receptor agonist with potential effect on the symptoms of ADHD. Objectives The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AZD1446 in adults with ADHD treated for 2 weeks. Method This was a randomized, double-blind, placebo-controlled crossover trial. Participants were 79 adults with ADHD, grouped according to their use of nicotine-containing products. Nicotine non-users received placebo and two of three AZD1446 treatment regimens (80 mg tid, 80 mg qd, 10 mg tid). Nicotine users received placebo, AZD1446 80 mg tid and 80 mg qd. Efficacy measures included the Conners' Adult ADHD Rating Scale and cognitive measures of immediate and delayed verbal episodic memory, learning, attention, working memory, executive functioning, and spatial problem solving (CogState computerized test battery). Results There was no significant effect of AZD1446 on any of the clinical scores irrespective of dose, schedule, or concomitant use of nicotine products. A statistically significant improvement was seen on the Groton Maze Learning Task, a measure of executive functioning, in nicotine non-users after treatment with AZD1446 80 mg qd. Conclusions AZD1446 was well tolerated, but did not significantly improve ADHD symptoms after 2 weeks of treatment compared to placebo. While the present study does not support the therapeutic utility of AZD1446 in ADHD, its potential pro-cognitive effects remain to be explored in other neuropsychiatric disorders.
- 3 May 2013
- Published by Springer Nature in Psychopharmacology
- Vol. 231 (6) , 1251-1265
A randomized, double-blind, placebo-controlled crossover study of α4β2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder
Rationale Stimulation of nicotinic cholinergic systems has been shown to alleviate ADHD symptoms and to improve cognitive performance. AZD1446 is a selective α4β2* nicotinic acetylcholine receptor agonist with potential effect on the symptoms of ADHD. Objectives The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AZD1446 in adults with ADHD treated for 2 weeks. Method This was a randomized, double-blind, placebo-controlled crossover trial. Participants were 79 adults with ADHD, grouped according to their use of nicotine-containing products. Nicotine non-users received placebo and two of three AZD1446 treatment regimens (80 mg tid, 80 mg qd, 10 mg tid). Nicotine users received placebo, AZD1446 80 mg tid and 80 mg qd. Efficacy measures included the Conners' Adult ADHD Rating Scale and cognitive measures of immediate and delayed verbal episodic memory, learning, attention, working memory, executive functioning, and spatial problem solving (CogState computerized test battery). Results There was no significant effect of AZD1446 on any of the clinical scores irrespective of dose, schedule, or concomitant use of nicotine products. A statistically significant improvement was seen on the Groton Maze Learning Task, a measure of executive functioning, in nicotine non-users after treatment with AZD1446 80 mg qd. Conclusions AZD1446 was well tolerated, but did not significantly improve ADHD symptoms after 2 weeks of treatment compared to placebo. While the present study does not support the therapeutic utility of AZD1446 in ADHD, its potential pro-cognitive effects remain to be explored in other neuropsychiatric disorders.
- 1 February 2012
- Published by Elsevier in Pediatric Neurology
- Vol. 46 (2) , 70-76
Diurnal Melatonin Patterns in Children: Ready to Apply in Clinical Practice?
- 1 February 2012
- Published by Elsevier in Pediatric Neurology
- Vol. 46 (2) , 70-76
Diurnal Melatonin Patterns in Children: Ready to Apply in Clinical Practice?
- 1 April 2010
- Published by Elsevier in Neuroscience
- Vol. 167 (1) , 104-110
Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study
- 1 April 2010
- Published by Elsevier in Neuroscience
- Vol. 167 (1) , 104-110
Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study
- 31 August 2008
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 18, S270-270
P.1.e.019 PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects
- 31 August 2008
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 18, S270-270
P.1.e.019 PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects